Home > Dermatology > AAD 2018 > What's hot in atopic dermatitis > IL-4/IL-13 inhibition

IL-4/IL-13 inhibition

Presented By
Prof. Eric Simpson, Oregon Health & Science University
Conference
AAD 2018
Trial
SOLO

IL-4/IL-13 inhibition: key factor in the AD pathogenesis

In the pathogenesis of AD, an immune dysfunction with an enhanced Th2 inflammation is as important as the epidermal barrier dysfunction.

Dupilumab, a potent blocker of IL4 and IL13, is the first biologic approved for the treatment of AD. Both cytokines are key mediators of TH2 inflammation, but also lower epidermal barrier proteins [16,17]. Dupilumab impacts both the inflammation and the barrier dysfunction in AD, thus targeting two key factors in AD pathogenesis.

As Prof. Eric Simpson, of Oregon Health & Science University, pointed out, about 50% of patients in the SOLO trial treated with a monotherapy of dupilumab gained an improvement in the EASI by 75% [18]. The efficacy is even higher when combined with topical steroids: 69% of patients gained an EASI 75 response, as was shown in the CHRONOS trial [19]. The one-year data of the CHRONOS trial have shown that the effect persists ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on